NRXS

NeurAxis, Inc. (NRXS) | Rumor.io

NeurAxis

NRXS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,667

Bullish sentiment (50-day avg)100%

Price to earnings ratio-7.8

Market capitalization92.9M

Earnings per share-0.76

Dividend yield (TTM)—

Revenue (annual)3.6M

Net income (annual)-7.8M

Social

What share of all stock conversation is about NRXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 16

$NRXS (NeurAxis, Inc.) announced new medical reimbursement coverage from a major national health insurer, expanding its covered lives by ~18M to over 120M.
The company's CEO stated that they are on pace to reach 7-8M covered lives for the full year, with a potential 4.5M in the second half.
$NRXS has been profitable when its run rate reaches 15M-17M, according to a post.

Generated by AI

Sentiment

Of the messages about NRXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.88% +16.15
Bearish	—	—	0% 0	4.12% -16.15

Bullish· Oct 24

$NRXS has the potential to make the company profitable and take off to $10 due to FDA clearance and a unique medical device.
The stock has a low float and can experience significant price movements, with a potential squeeze to $7.50+.
With no debt and good news, $NRXS could see prices above $8, and its low float of 1.4 million shares makes it a strong candidate for a 100%+ increase.

Bearish· Oct 24

The price movement of $NRXS has been disappointing, with the stock struggling to bounce off $4.4.
The release of similar news on May 20, which previously resulted in a significant price increase, has not had the same effect, leading to a decline in the stock's value.
Insiders may have been selling off shares over the past 6 months, contributing to the stock's 11.53% decline, and the company's recent offering may have negatively impacted sentiment.

Generated by AI

Topics

Of the messages about NRXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	94.82%	82.75%
Analysts	—	—	0%	4.68%
Technical Analysis	—	—	5.18%	10.38%
Controversies	—	—	0%	1.75%
Earnings	—	—	0%	0.44%
Macro	—	—	0%	0%

Announcements· Oct 24

NeurAxis, Inc. ($NRXS) received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) technology to treat functional abdominal pain associated with functional dyspepsia (FD) in patients aged 8 and older.
This marks the first FDA approval for the treatment of pain and associated nausea associated with functional dyspepsia in adult patients, expanding NeurAxis' total addressable market.
NeurAxis' PENFS technology has been cleared for use in treating functional abdominal pain and nausea associated with functional dyspepsia in patients aged 8 and older, representing a significant expansion of the company's addressable market.

Technical Analysis· May 20

$NRXS is likely to break double digits before the end of the day on Friday, according to some analysts.
The stock's recent price action has been characterized by rejection at the $7.01 level, with some traders expecting another dip before a potential price increase.
Technical analysis suggests that $NRXS has a strong resistance level at $3.90, which could be a key indicator of the stock's future price movement.

Generated by AI

Community

Of the messages about NRXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	87.19%	33.43%
Newcomers	—	0%	12.81%	66.57%

Oct 24

The FDA has granted clearance for NeurAxis's percutaneous electrical nerve stimulation platform to treat functional dyspepsia, a condition causing chronic pain in the abdomen.
NeurAxis's stock has shown strong momentum after the company's Q2 growth and the approval of a new CPT reimbursement code, leading to a 29% pre-market increase.
The company's PENFS technology has received FDA 510(k) clearance for treating functional abdominal pain associated with functional dyspepsia, and its stock is currently trading with a high short interest, indicating potential volatility.

Generated by AI

News

NeurAxis appoints Craig Blanchard as chief commercial officer

23h agoInvesting.com

NeurAxis secures major insurer coverage for IB-Stim device

13d agoInvesting.com

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

Total national coverage footprint for PENFS increases to over 120 million covered livesCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The c

13d agoYahoo! Finance Canada

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. Company Webcast The webcast presentation will take place

14d agoYahoo Finance Australia

Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.

14d agoYahoo Finance

NeurAxis at iAccess Alpha conference: payer wins drive growth

14d agoInvesting.com

Also Discussed

Investors talking about NRXS also mention

#	Name	Attention
1	QIPT - Quipt Home Medical Corp.	——
2	Vsee Health Inc.VSEE	0%0
3	MetaVia Inc.MTVA	0%0
4	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
5	CFSB - CFSB Bancorp, Inc.	——
6	Xilio Therapeutics, Inc.XLO	0%0
7	Genenta Science S.p.A. Sponsored ADRGNTA	0%0
8	CBL International Ltd. Class B Ordinary SharesBANL	0%0
9	Harrow Inc.HROW	0%0
10	DevvStream Corp.DEVS	0%0

NeurAxis, Inc.

Healthcare
Biotechnology

NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions, with an emphasis on disorders of the gut-brain interaction. Its current product portfolio centers on IB-Stim, a drug-free, non-surgical device worn behind the ear and designed to deliver percutaneous electrical nerve field stimulation for patients with functional abdominal pain associated with irritable bowel syndrome, functional dyspepsia, and related nausea symptoms. The company serves pediatric and adult patients through healthcare settings such as hospitals and clinics, where its therapies are used to support symptom management in targeted gastrointestinal conditions. NeurAxis also works to commercialize evidence-based devices that address unmet needs in digestive health and related neuromodulation care. Headquartered in Carmel, Indiana, NeurAxis operates as a specialized player in the medical device market with a focus on non-invasive treatment options.

Website

Location

11611 North Meridian St

Carmel, IN, 46032

United States

Social

What share of all stock conversation is about NRXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 16

$NRXS (NeurAxis, Inc.) announced new medical reimbursement coverage from a major national health insurer, expanding its covered lives by ~18M to over 120M.
The company's CEO stated that they are on pace to reach 7-8M covered lives for the full year, with a potential 4.5M in the second half.
$NRXS has been profitable when its run rate reaches 15M-17M, according to a post.

Generated by AI

Sentiment

Of the messages about NRXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.88% +16.15
Bearish	—	—	0% 0	4.12% -16.15

Bullish· Oct 24

$NRXS has the potential to make the company profitable and take off to $10 due to FDA clearance and a unique medical device.
The stock has a low float and can experience significant price movements, with a potential squeeze to $7.50+.
With no debt and good news, $NRXS could see prices above $8, and its low float of 1.4 million shares makes it a strong candidate for a 100%+ increase.

Bearish· Oct 24

The price movement of $NRXS has been disappointing, with the stock struggling to bounce off $4.4.
The release of similar news on May 20, which previously resulted in a significant price increase, has not had the same effect, leading to a decline in the stock's value.
Insiders may have been selling off shares over the past 6 months, contributing to the stock's 11.53% decline, and the company's recent offering may have negatively impacted sentiment.

Generated by AI

Topics

Of the messages about NRXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	94.82%	82.75%
Analysts	—	—	0%	4.68%
Technical Analysis	—	—	5.18%	10.38%
Controversies	—	—	0%	1.75%
Earnings	—	—	0%	0.44%
Macro	—	—	0%	0%

Announcements· Oct 24

NeurAxis, Inc. ($NRXS) received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) technology to treat functional abdominal pain associated with functional dyspepsia (FD) in patients aged 8 and older.
This marks the first FDA approval for the treatment of pain and associated nausea associated with functional dyspepsia in adult patients, expanding NeurAxis' total addressable market.
NeurAxis' PENFS technology has been cleared for use in treating functional abdominal pain and nausea associated with functional dyspepsia in patients aged 8 and older, representing a significant expansion of the company's addressable market.

Technical Analysis· May 20

$NRXS is likely to break double digits before the end of the day on Friday, according to some analysts.
The stock's recent price action has been characterized by rejection at the $7.01 level, with some traders expecting another dip before a potential price increase.
Technical analysis suggests that $NRXS has a strong resistance level at $3.90, which could be a key indicator of the stock's future price movement.

Generated by AI

Community

Of the messages about NRXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	87.19%	33.43%
Newcomers	—	0%	12.81%	66.57%

Oct 24

The FDA has granted clearance for NeurAxis's percutaneous electrical nerve stimulation platform to treat functional dyspepsia, a condition causing chronic pain in the abdomen.
NeurAxis's stock has shown strong momentum after the company's Q2 growth and the approval of a new CPT reimbursement code, leading to a 29% pre-market increase.
The company's PENFS technology has received FDA 510(k) clearance for treating functional abdominal pain associated with functional dyspepsia, and its stock is currently trading with a high short interest, indicating potential volatility.

Generated by AI

NeurAxis

Social

Sep 16

Bullish· Oct 24

Bearish· Oct 24

Announcements· Oct 24

Technical Analysis· May 20

Oct 24

NeurAxis appoints Craig Blanchard as chief commercial officer

NeurAxis secures major insurer coverage for IB-Stim device

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

NeurAxis at iAccess Alpha conference: payer wins drive growth

Also Discussed

NeurAxis, Inc.

Company Information

Location

NeurAxis appoints Craig Blanchard as chief commercial officer

NeurAxis secures major insurer coverage for IB-Stim device

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

NeurAxis at iAccess Alpha conference: payer wins drive growth

Also Discussed

Social

Sep 16

Bullish· Oct 24

Bearish· Oct 24

Announcements· Oct 24

Technical Analysis· May 20

Oct 24